The cost-effectiveness of aspirin versus
โ
Chin Hur; Lee S. Simon; G. Scott Gazelle
๐
Article
๐
2004
๐
John Wiley and Sons
๐
English
โ 122 KB
## BACKGROUND. Aspirin therapy is accepted widely for secondary prevention in patients with documented cardiovascular disease, but there is a growing trend among healthy individuals to use aspirin as primary chemoprevention for both cardiovascular and oncologic diseases. Accruing evidence suggests